Previous 10 | Next 10 |
Pluristem Therapeutics (PSTI) slumps 42% premarket in reaction to recommendation letter by the independent Data Monitoring Committee ((DMC)) of its global Phase III study for the treatment of critical limb ischemia ((CLI)).The clinical dataset was reviewed for safety and analys...
Atossa Therapeutics (ATOS) -42% on announcing pricing of $20M underwritten public offering.Pluristem Therapeutics (PSTI) -42% after DMC recommendation following interim analysis of its Phase III CLI study.Photronics PLAB -18% on Q4 earnings release.Talos Energy TALO -...
The CLI study is unlikely to meet its primary endpoint by the time of the final analysis Substantial low number of events in the placebo group in the CLI study decreased the statistical power of the study to meet its primary endpoint ...
Pluristem's CLI Phase III trial interim results should be published soon. Results are critical and might define the fate of the company. CLI potential market is immense. Possible company\stock reaction post results. For further details see: Pluristem - Moment Of Trut...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Satu...
PLX-R18 d emonstrated significant c linical improvements in Hb, ANC, and PLT among the high-dose cohort PLX-R1 8 was found to be safe and well-tolerated T opline results from the full Phase I clinical trial ...
HAIFA, Israel, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI) , a leading regenerative medicine company developing a platform of novel biological products, today named medical experts to form the Steering Committee for its c...
The following slide deck was published by Pluristem Therapeutics Inc. in conjunction with this event. For further details see: Pluristem Therapeutics (PSTI) - Investor Presentation - Slideshow
Two new sample breakout stocks for Week 43 with better than 10% short-term upside potential. Now up an average +241.2% YTD. Last week LITB gained +37.2% and RYTM gained +8.13% with all four selections averaging +5.7% to the close again outperforming the S&P 500. The streak of ...
Regeneron announces FDA approval for Ebola treatment REGN-EB3. Pluristem receives approval for Cohort II of Chronic Graft vs. Host Disease Study. AnaptysBio announces positive data from Phase 3 Imsidolimab trial. For further details see: Regeneron's Ebola Approval, And O...
News, Short Squeeze, Breakout and More Instantly...
Pluristem Therapeutics Inc. Company Name:
PSTI Stock Symbol:
NASDAQ Market:
Pluristem Therapeutics Inc. Website:
HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief Executi...
As of July 26 , 2022 , Pluri ’s stock will trade under the symbol PLUR The new name reflects the Company ’s strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cel...
The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdiJpA HAIFA, Israel, Ju...